Interactions between thrombophilic genetic mutations and clinical bleeding in patients on chronic oral anticoagulant treatment

Haematologica. 2005 Dec;90(12):1720-2.

Abstract

We studied the prevalence of genetic thrombophilic mutations in patients on chronic oral anticoagulant treatment (OAT) who had bleeding complications. In a case-control study we found ten (12.8%) carriers of factor V Leiden and two (2.5%) carriers of the PT20210A mutation among 78 patients with a history of moderate-severe bleeding while on OAT, and seven (4.4%) and four (2.5%), respectively, among 156 matched patients with no bleeding while on OAT (odds ratio 3.1+/-1.6, p=0.026). In patients on chronic OAT, FV Leiden is a risk factor for moderate-severe bleeding.

Publication types

  • Letter

MeSH terms

  • 3' Untranslated Regions
  • Acenocoumarol / administration & dosage
  • Acenocoumarol / adverse effects
  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects*
  • Case-Control Studies
  • Factor V / analysis
  • Factor V / genetics
  • Female
  • Follow-Up Studies
  • Gene Frequency
  • Hemorrhage / chemically induced*
  • Hemorrhage / genetics*
  • Hospitalization / statistics & numerical data
  • Humans
  • International Normalized Ratio
  • Male
  • Middle Aged
  • Prevalence
  • Prothrombin / genetics
  • Sample Size
  • Thrombophilia / epidemiology
  • Thrombophilia / genetics*
  • Warfarin / administration & dosage
  • Warfarin / adverse effects

Substances

  • 3' Untranslated Regions
  • Anticoagulants
  • factor V Leiden
  • Warfarin
  • Factor V
  • Prothrombin
  • Acenocoumarol